Pfizer (PFE) Gets a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer, with a price target of $28.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Flynn is a 5-star analyst with an average return of 9.8% and a 56.21% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna.
In addition to Morgan Stanley, Pfizer also received a Hold from J.P. Morgan’s Chris Schott in a report issued today. However, on April 7, RBC Capital maintained a Sell rating on Pfizer (NYSE: PFE).
Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.56 billion and a GAAP net loss of $1.65 billion. In comparison, last year the company earned a revenue of $17.76 billion and had a net profit of $403 million
Read More on PFE:
Disclaimer & DisclosureReport an Issue
- Pfizer price target lowered to $26 from $27 at BofA
- Option traders moderately bearish in Pfizer with shares down 2.5%
- Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
- Pfizer Targets Advanced Kidney Cancer With New PF-08634404 Trial: What Investors Should Know
- Mixed options sentiment in Pfizer with shares down 1.57%
